Case reports indicate that symptoms appear months to years after olmesartan initiation.
Despite being the seventh ARB approved by the Food and Drug Administration and despite a lack of hard outcome trial data supporting its use, olmesartan is widely prescribed, with estimated worldwide sales of 2 billion US dollars in 2009.
Patients with renal insufficiency have elevated serum concentrations of olmesartan compared to subjects with normal renal function.
Severe, chronic diarrhea with considerable weight loss may develop months to years after starting olmesartan.
For those who cannot afford the cost of olmesartan, certain patient assistance programs are available.
Concurrent administration of bile acid sequestering agent colesevelam hydrochloride reduces the systemic exposure and peak plasma concentration of olmesartan.